XBI The mid-June 143% of $XBI units short as percent of Units outstanding, is highest since April 3rd 2020 Covid crash low reading of 155%. XBI subsequently rallied from $75 to $170 (+125%) at the Feb 2021 peak, from where our hangover persists. Similarly, after low in July 2014 from the Janet Yellen "#biotech is in a bubble" comment, the short interest hit a then record high of 128%. XBI rallies from $44 to $90 (+100%) over the next year. Yet another measure of hate priced into biotech. Past is not necessarily prologue, but even a tiny sliver is better than the past 4 years.
XBI Leerink:" Biopharma Cash Runway Map: Bottom Line: Amid significant macroeconomic challenges for the Biopharma sector, we update our cash runway map for "not-yetprofitable" companies across the Leerink Partners' Biopharma Coverage Universe. The map highlights value (with >2 years cash runway, trading below cash) and growth stocks (with >2 years of cash runway, trading above cash), as well as high-volatility catalyst plays (<2 years of cash runway, trading above cash) and stocks with near-term financial overhangs (<2 years cash runway, trading below cash), within each sub-sector. ● Across our Biopharma coverage universe, as of June 2025, ~51% of currently unprofitable covered companies had >2 years of cash runway, up from 40% in June 2023...."
Cuanto más a la derecha, más pasta les queda. La mitad del cuadro son 2 años. Cuanto más abajo, más por debajo de cash (tienen más dinero que la capitalización de la empresa contando deudas), la mitad es ev 0.
Las del cuarto inferior derecho tienen más de 2 años de pasta pero están cotizando negativo, muchas veces con razón y son arriesgadas, pero también más recompensa potencial.
